Key MessagesThe present data from the NeuroEPIC4PD study show a robust inverse association between smoking status at recruitment and Parkinson's disease (PD) risk with a dose--response relationship with smoking duration and intensity.These inverse relationships were replicated across different clinical subtypes.An inverse association between exposure to passive smoking at home and/or at work and risk of PD was also identified.Explanation alternatives to a causal association including a delaying effect of smoking on disease onset, reverse causality, and unmeasured and residual confounding have been discussed in order to reinforce causal inference using observational data.

Background
==========

An overwhelming amount of evidence exists on the inverse association between cigarette smoking and Parkinson's disease (PD). The inverse association is strong and consistent across studies,[@dyy230-B1] stronger for current smokers than for former smokers when compared with non-smokers.[@dyy230-B1]^,^[@dyy230-B2] Some studies suggest that smoking duration is more strongly associated with a reduced risk of PD compared with smoking intensity.[@dyy230-B3] The overall association appears consistent in men and women[@dyy230-B1] and not confounded or modified by educational level. A comparable inverse association was also observed for pipe and cigar smoking in men[@dyy230-B4] and for smokeless tobacco.[@dyy230-B5]^,^[@dyy230-B6] An attempt to demonstrate causality of the association has been made using parental smoking as an instrumental variable: it was shown that children of smokers---who are more likely to smoke themselves---are at decreased risk of PD even if they do not smoke.[@dyy230-B7]

Nonetheless, there is still considerable caution in interpreting this association as protective. Few theories have been postulated to explain the current evidence in a non-causal way and these are summarized with Direct Acyclic Graphs (DAGs) in [Figure 1](#dyy230-F1){ref-type="fig"}. Some studies failed to replicate the association in cases with an older age of onset[@dyy230-B3]^,^[@dyy230-B8] leading to the hypothesis that smoking might delay, not prevent, PD onset ([Figure 1B](#dyy230-F1){ref-type="fig"}). The most intriguing, and more difficult to prove, is a possible confounding effect by a low-risk-taking personality trait that would be regarded as an unmeasured confounder if it is genetically determined or as reverse causation if it is triggered by dopamine shortage[@dyy230-B9]^,^[@dyy230-B10] ([Figure 1C and D](#dyy230-F1){ref-type="fig"}). According to this, and coherently with the involvement of dopamine in the brain-rewarding circuits,[@dyy230-B11] people who will subsequently develop PD tend to have a low-risk-taking personality, which makes them less likely to smoke or more likely to quit. Coherently, before disease onset, people with PD might find it easier to quit smoking compared with those without PD[@dyy230-B12] ([Figure 1D](#dyy230-F1){ref-type="fig"}). Nonetheless, the inverse association between smoking intensity and PD observed among monozygotic twins argues against a major role of genetics and/or personality.[@dyy230-B13] Given that personality trait would have a lesser role in influencing the exposure to passive smoking, demonstrating a decreased risk of PD among those exposed to passive smoking would overcome this effect; however, a previous study failed to find it.[@dyy230-B14]

![Direct Acyclic Graphs (DAGs) showing the hypotheses on the observed association between cigarette smoking and Parkinson's disease. (**A**) Smoking protects against PD (causal effect); (**B**) smoking delays PD onset; (**C**) subjects with a specific personality trait are both less likely to smoke and more susceptible to PD (confounding effect); (**D**) subtle dopaminergic changes before disease onset make quitting smoking easier (reverse causality).](dyy230f1){#dyy230-F1}

Clarifying the causal nature of the association between smoking and PD would contribute to understanding the mechanisms underlying the disease, informing potential targets for preventive or early treatments. Moreover, no data are currently available on the consistency of the inverse association between smoking and PD across clinical subtypes.

The aim of this study is to assess the association between smoking patterns (duration, amount and time since quitting smoking) and PD risk. Specifically, the potential delaying effect; the consistency of smoking patterns among current and former smokers to interrogate any reverse causality; the association with passive smoking; and the consistency of the association across clinical subtypes will be investigated.

Methods
=======

Population
----------

The NeuroEPIC4PD study involved 220 494 subjects recruited in Sweden, the UK, the Netherlands, Germany, Spain, Italy and Greece from the general population residing in defined geographical areas between 1992 and 2002 and aged 37--70 years, within the European Presepctive Investigation into Cancer and Nutrition (EPIC) study.[@dyy230-B15] Exception was the Utrecht cohort, which was based on breast-cancer-screening participants.[@dyy230-B15] The Naples and Utrecht cohorts were restricted to women, whereas all other cohorts involved both sexes. To date, follow-up is 98.5% complete and the median follow-up time of this sample is 12.8 years \[inter-quartile range (IQR) 11.5--14.2\].

Case ascertainment and sample size
----------------------------------

A total of 881 PD cases was ascertained in the participating EPIC centres.[@dyy230-B16] The present analysis has been conducted on a total sample of 214 533 subjects (including 715 incident PD cases) after removing 147 prevalent PD cases, 5359 subjects (including 19 PD cases) with missing information on smoking status at recruitment. Moreover, 221 subjects with PD-like conditions \[Multi-System Atrophy (MSA) *N* = 24; Progressive Sopra-nuclear Palsy (PSP), *N* = 21; vascular parkinsonism, *N* = 34; Lewy Body Dementia (LBD), *N* = 34; essential tremor, *N* = 27; PD with essential tremor, *N* = 9; and unclassified parkinsonism, *N* = 72\] were also removed from the analysis. The sample resulted in a total of 2 666 206 person/years. Procedures for PD case ascertainment in the EPIC cohort have been described elsewhere.[@dyy230-B16] In brief, in each centre, potential cases were identified through record linkage and validated through clinical record review by a neurologist expert in movement disorder who collected additional clinical data, including age of onset (defined as age when the first motor symptom was noticed) and clinical subtype at onset (tremor-dominant, postural instability/gait disturbance, akinetic-rigid forms).[@dyy230-B16]

Smoking characteristics
-----------------------

Answers to a number of questions on present and past smoking habits were collected at recruitment in the EPIC study. These included smoking status at recruitment (never, former and current smoker), age when they started smoking and quit, and number of cigarettes/day smoked at different ages. This latter information was not collected in Sweden, which was therefore excluded from all analyses on smoking intensity (*n* = 53 291). Starting from this core information, a number of variables were derived: duration of smoking (never smokers, smokers for \<20, 20--29, 30+ years) missing for 4620 individuals; smoking intensity as mean lifetime cigarettes/day (never smokers, \<12, 12+ cigarettes/day) missing for 10 876 individuals; time since quitting smoking, namely number of years elapsed from quitting smoking and recruitment to the cohort (never smoker, 19+, 9--18, \<9 years) missing for 2221 individuals; age when quit smoking (never smoker, \<33, 34--43, 44+ years) missing for 2221 individuals; and age when started smoking (never smoker, 20+, 17--19, \<16 years) missing for 3011 individuals. Information on second-hand smoke (SHS) exposure was available only in a few centres: participants were asked whether any of their parents smoked when they were children in Italy, the Netherlands and Sweden (*N* = 59 329), whereas information on current SHS exposure at home or work was available only for participants recruited in Italy and Sweden (*N* = 40 816).

Additional information collected at baseline and relevant for this analysis is the highest educational level attained (none/primary, technical, secondary, university).

Statistical analysis
--------------------

Cox-regression models using age as the underlying time variable, adjusted for level of education and sex, and stratified for centre and age at recruitment, were run in order to investigate the effects of the main smoking variables in relation to PD onset. Models investigating smoking status, duration and amount of smoking, time and age since quitting smoking for former smokers and age when started smoking were investigated and *p*-values for trend across categories calculated where appropriate. Analyses were repeated using never smokers as the reference category where appropriate, in men and women separately, and restricted to tremor-dominant and akinetic-rigid forms of PD at onset. Heterogeneity across country was tested using the approach proposed by Smith *et al.*[@dyy230-B17] Heterogeneity was assessed by the likelihood ratio of two stratified models: one with country-specific estimates and one with overall estimates. Under the null hypothesis of no heterogeneity, this statistic follows approximately a chi-square distribution on (*k* -- 1)\*(*j* -- 1) degrees of freedom (where *k* is the number of categories of smoking variable and *j* is the total number of countries).

In order to investigate a potential delaying effect of smoking on PD onset, possible non-proportionality was assessed using the Schoenfeld residuals.[@dyy230-B18] Also, the analysis on the main three smoking variables was repeated on the mid-age of PD onset after excluding subjects with an onset at 70+ years (\<70 years, *N* = 385) or on late PD onset, after excluding those with an age of onset younger than 70 years (70+ years, *N* = 330). Studying separately subjects with a young age at onset (≤50 years) was not possible, as there were only 12 such cases.

For indirectly exploring reverse causality, the Cox regression exploring the dose--response relationships between smoking intensity and duration were repeated among current and former smokers at recruitment separately.

Both variables on SHS (in infancy and at recruitment) where studied in relation to PD onset in Cox-regression models repeated in never smokers only in an attempt to overcome unmeasured and residual confounding of the main association.

Finally, for exploring the possible competing risk of mortality in the smoker group, a competing-risk survival analysis was carried out using death as a competing event and the Fine and Gray regression model.[@dyy230-B19]

A sensitivity analysis was conducted repeating the main Cox models using definite and very likely PD diagnosis only (389 PD cases). For further detail on how cases were labelled, please refer to the methodological paper.[@dyy230-B16] All analyses were done using STATA 12 IC and R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).

No direct patient involvement was needed to run this study, which was based on data previously collected.

Results
=======

Demographic characteristics and smoking habits for men and women in the EPIC cohort and PD cases are described in [Table 1](#dyy230-T1){ref-type="table"}. Former smokers at recruitment had a ∼20% reduced risk of developing PD during follow-up compared with never smokers; current smokers had a halved risk compared with never smokers ([Table 2](#dyy230-T2){ref-type="table"}). These results were highly consistent in men and women ([Table 3](#dyy230-T3){ref-type="table"}) and no heterogeneity was detected across countries ([Table 4](#dyy230-T4){ref-type="table"}). The difference in incidence rates across countries is more likely due to local differences in case-ascertainment procedures rather than true difference in incidence, as discussed in.[@dyy230-B16]

###### 

Demographic characteristics and smoking habits among men and women with and without PD at recruitment in the EPIC Study

                                                                        Total        Men              Women                                     
  --------------------------------------------------------------------- ------------ ---------------- ------------ --------------- ------------ ---------------
  **Age at recruitment, mean (SD)**                                     61.4 (8.3)   53.0 (10.0)      61.7 (8.3)   53.1 (10.1)     61.3 (8.3)   53.0 (9.9)
  **Age at onset, mean (SD)** [^a^](#tblfn1){ref-type="table-fn"}       67.5 (7.9)                    67.6 (7.8)                   67.3 (8.0)   
  **Smoking status at recruitment**                                                                                                             
   Never smoker, %                                                      402 (56.2)   101 958 (47.7)   149 (40.7)   26 969 (33.7)   253 (72.5)   74 989 (56.1)
   Former smoker, %                                                     232 (32.5)   59 653 (27.9)    165 (45.1)   29 976 (37.5)   67 (19.2)    29 677 (22.2)
   Current smoker, %                                                    81 (11.3)    52 207 (24.4)    52 (14.2)    23 078 (28.8)   29 (8.3)     29 129 (21.8)
  **Duration of smoking** [^b^](#tblfn2){ref-type="table-fn"}                                                                                   
  \<20 years, %                                                         92 (32.4)    36 243 (33.8)    57 (28.6)    15 013 (29.6)   35 (41.2)    21 230 (37.6)
   20--29 years, %                                                      69 (24.3)    32 425 (30.2)    47 (23.6)    15 171 (29.9)   22 (25.9)    17 254 (30.5)
   30+ years, %                                                         123 (43.3)   38 601 (36.0)    95 (47.7)    20 551 (40.5)   28 (32.9)    18 050 (31.9)
  **Lifetime cigarettes/day** [^c^](#tblfn3){ref-type="table-fn"}                                                                               
  \<12 cigarettes/day, %                                                91 (50.3)    35 132 (47.8)    56 (41.5)    11 085 (31.2)   35 (76.1)    24 047 (63.4)
   12+ cigarettes/day, %                                                90 (49.7)    38 370 (52.2)    79 (58.5)    24 478 (68.8)   11 (23.9)    13 892 (36.6)
  **Time since quitting smoking** [^d^](#tblfn4){ref-type="table-fn"}                                                                           
   19+ years, %                                                         110 (50.7)   19 737 (34.4)    82 (52.9)    10 151 (35.3)   28 (45.2)    9586 (33.5)
   9--18 years, %                                                       58 (26.7)    19 295 (33.6)    40 (25.8)    9773 (33.9)     18 (29.0)    9522 (33.2)
  \<9 years, %                                                          49 (22.6)    18 415 (32.1)    33 (21.3)    8874 (30.8)     16 (25.8)    9541 (33.0)
  **Age when quit smoking** [^d^](#tblfn4){ref-type="table-fn"}                                                                                 
  \<33 years, %                                                         54 (24.9)    18 330 (31.9)    44 (28.4)    8 354 (29.0)    10 (16.1)    9 976 (34.8)
   33--43 years, %                                                      53 (24.4)    19 086 (33.2)    33 (21.3)    9809 (34.1)     20 (32.3)    9277 (32.4)
   44+ years, %                                                         110 (50.7)   20 031 (34.9)    78 (50.3)    10 635 (369)    32 (51.6)    9396 (32.8)
  **Age when started smoking** [^e^](#tblfn5){ref-type="table-fn"}                                                                              
   20+ years, %                                                         136 (46.0)   43 194 (36.7)    75 (36.1)    17 192 (33.3)   61 (69.3)    26 002 (45.4)
   17--19 years, %                                                      74 (25.0)    31 984 (29.4)    61 (29.3)    14 975 (29.0)   13 (14.8)    17 009 (29.7)
  \<16 years, %                                                         86 (29.1)    33 688 (30.9)    72 (34.6)    19 458 (37.7)   14 (15.9)    14 230 (24.9)
  **Educational level** [^f^](#tblfn6){ref-type="table-fn"}                                                                                     
   None/primary, %                                                      389 (56.1)   94 988 (44.8)    192 (54.1)   33 823 (42.7)   197 (58.3)   61 165 (46.1)
   Technical, %                                                         148 (21.4)   46 407 (21.9)    73 (20.6)    18 173 (22.9)   75 (22.2)    28 234 (21.3)
   Secondary, %                                                         69 (10.0)    33 145 (15.7)    38 (10.7)    11 788 (14.9)   31 (9.2)     21 357 (16.1)
   University or above, %                                               87 (12.6)    37 275 (17.6)    52 (14.7)    15 463 (19.5)   35 (10.4)    21 812 (16.5)
  **Passive smoking**                                                                                                                           
   In childhood[^g^](#tblfn7){ref-type="table-fn"}, %                   100 (64.1)   42 491 (71.8)    36 (67.9)    8101 (66.4)     64 (62.1)    34 390 (73.2)
   At home or at work[^h^](#tblfn8){ref-type="table-fn"}, %             86 (62.3)    27 941 (68.7)    34 (63.0)    9102 (74.6)     52 (61.9)    18 839 (66.1)

233 missing values (138 men and 85 women).

Calculated on ever smokers only, 4620 missing values.

Calculated on ever smokers only after excluding Swedish subjects (*N* = 53 291), 10 876 missing values.

Calculated on former smokers only, 2221 missing values.

Calculated on ever smokers only, 3011 missing values.

Not including 2025 subjects with undetermined educational level.

Available for 59 329 individuals only.

Available for 40 816 individuals only.

###### 

Cox-regression analyses showing hazard ratios (HRs) \[and relative 95% confidence intervals (CIs)\] and using as reference category never smokers or the appropriate category for each variable and HRs (and 95% CIs) for competing-risk models using mortality as competing risk

                                                                      PD cases   HR (95% CI)         HR (95% CI)         Competing-risk HR (95% CI)^a^
  ------------------------------------------------------------------- ---------- ------------------- ------------------- -------------------------------
  **Smoking status at recruitment**                                                                                      
   Never smokers                                                      402        1.00                                    1.00
   Former smokers                                                     232        0.79 (0.66--0.94)                       0.75 (0.63--0.89)
   Current smokers                                                    81         0.49 (0.38--0.63)                       0.44 (0.35--0.57)
  **Duration of smoking** [^b^](#tblfn10){ref-type="table-fn"}                                                           
   Never smokers                                                      402        1.00                                    1.00
  \<20 years                                                          92         0.84 (0.67--1.07)   1.00                0.81 (0.64--1.02)
   20--29 years                                                       69         0.73 (0.56--0.96)   0.87 (0.63--1.19)   0.67 (0.51--0.87)
   30+ years                                                          123        0.54 (0.43--0.66)   0.61 (0.46--0.80)   0.49 (0.40--0.61)
                                                                                 \<0.001             \<0.001             \<0.001
  **Smoking intensity** [^c^](#tblfn11){ref-type="table-fn"}                                                             
   Never smokers                                                      284        1.00                                    1.00
  \<12 cigarettes/day                                                 91         0.80 (0.62--1.02)   1.00                0.77 (0.60--0.98)
   12+ cigarettes/day                                                 90         0.54 (0.42--0.71)   0.69 (0.50--0.94)   0.49 (0.38--0.64)
                                                                                 \<0.001             0.020               \<0.001
  **Time since quit smoking** [^d^](#tblfn12){ref-type="table-fn"}                                                       
   Never smokers                                                      402        1.00                                    1.00
   19+ years                                                          110        0.87 (0.69--1.09)   1.00                0.85 (0.68--1.06)
   9--18 years                                                        58         0.71 (0.53--0.95)   0.81 (0.58--1.12)   0.65 (0.49--0.87)
  \<9 years                                                           49         0.68 (0.50--0.93)   0.80 (0.56--1.14)   0.65 (0.48--0.88)
                                                                                 0.002               0.173               \<0.001
  **Age when quit smoking** [^d^](#tblfn12){ref-type="table-fn"}                                                         
   Never smokers                                                      402        1.00                                    1.00
  \<33 years                                                          54         0.94 (0.70--1.26)   1.00                0.90 (0.67--1.20)
   34--43 years                                                       53         0.71 (0.52--0.95)   0.76 (0.52--1.12)   0.69 (0.51--0.93)
   44+ years                                                          110        0.74 (0.59--0.93)   0.78 (0.55--1.11)   0.69 (0.55--0.87)
                                                                                 0.003               0.217               \<0.001
  **Age when started smoking** [^e^](#tblfn13){ref-type="table-fn"}                                                      
   Never smokers                                                      402        1.00                                    1.00
   20+ years                                                          136        0.74 (0.61--0.91)   1.00                0.70 (0.57--0.85)
   17--19 years                                                       74         0.59 (0.45--0.76)   0.76 (0.56--1.03)   0.56 (0.44--0.72)
  \<16 years                                                          86         0.63 (0.49--0.81)   0.78 (0.58--1.05)   0.57 (0.45--0.73)
                                                                                 \<0.001             0.095               \<0.001
  **Passive smoking in childhood**                                    56         1.00                                    1.00
                                                                      100        0.99 (0.71--1.40)                       0.97 (0.69--1.36)
                                                                                 0.995                                   0.862
  **Passive smoking at home/work**                                    52         1.00                                    1.00
                                                                      86         0.70 (0.49--0.99)                       0.71 (0.50--1.01)
                                                                                 0.047                                   0.059

Restricted to the whole cohort except Sweden.

Calculated after excluding 4620 (of which 29 PD) missing values.

Calculated after excluding 10 876 missing values (of which 55 PD cases).

Calculated after excluding 54 509 (of which 96 PD cases) missing values.

Calculated after excluding 3011 (of which 17 PD cases) missing values.

###### 

Hazard ratios (HRs) and relative 95% confidence intervals (CIs) from Cox-regression models investigating smoking variables in relation to PD onset in men and women separately and sensitivity analysis including only definite and very likely PD cases

                                                               Men     Women               All                                 
  ------------------------------------------------------------ ------- ------------------- ------- ------------------- ------- -------------------
  **Smoking status at recruitment**                                                                                            
   Never smokers                                               149     1.00                253     1.00                228     1.00
   Former smokers                                              165     0.77 (0.62--0.97)   67      0.80 (0.60--1.07)   121     0.85 (0.66--1.08)
   Current smokers                                             52      0.49 (0.35--0.67)   29      0.46 (0.31--0.69)   40      0.42 (0.29--0.59)
  **Duration of smoking**                                                                                                      
   Never smokers                                               149     1.00                253     1.00                228     1.00
  \<20 years                                                   57      0.83 (0.61--1.14)   35      0.83 (0.58--1.21)   55      0.98 (0.72--1.34)
   20--29 years                                                47      0.76 (0.54--1.06)   22      0.68 (0.43--1.07)   33      0.64 (0.44--0.94)
   30+ years                                                   95      0.55 (0.42--0.72)   28      0.45 (0.30--0.67)   64      0.52 (0.39--0.70)
                                                               Trend   \<0.001             Trend   \<0.001             Trend   \<0.001
  **Smoking intensity** [^b^](#tblfn15){ref-type="table-fn"}                                                                   
   Never smokers                                               149     1.00                253     1.00                228     1.00
  \<12 cigarettes/day                                          56      0.79 (0.57--1.10)   35      0.83 (0.58--1.25)   51      0.85 (0.61--1.19)
   12+ cigarettes/day                                          79      0.56 (0.42--0.76)   11      0.53 (0.28--0.99)   46      0.47 (0.33--0.68)
                                                               Trend   \<0.001             Trend   0.043               Trend   \<0.001
  **Time since quitting smoking**                                                                                              
   Never smoker                                                149     1.00                253     1.00                228     1.00
   19+ years                                                   82      0.89 (0.67--1.18)   28      0.79 (0.53--1.19)   58      1.05 (0.77--1.44)
   9--18 years                                                 40      0.68 (0.48--0.97)   18      0.78 (0.48--1.27)   28      0.67 (0.45--1.01)
  \<9 years                                                    33      0.66 (0.45--0.97)   16      0.73 (0.44--1.23)   30      0.75 (0.50--1.11)
                                                               Trend   0.008               Trend   0.106               Trend   0.046
  **Age when quitting smoking**                                                                                                
   Never smoker                                                149     1.00                253     1.00                228     1.00
  \<33 years                                                   44      1.10 (0.78--1.55)   10      0.56 (0.29--1.07)   36      1.25 (0.86--1.80)
   34--43 years                                                33      0.60 (0.41--0.88)   20      0.96 (0.60--1.53)   28      0.74 (0.49--1.11)
   44+ years                                                   78      0.72 (0.54--0.97)   32      0.77 (0.52--1.12)   52      0.73 (0.53--1.01)
                                                               Trend   0.006               Trend   0.164               Trend   0.032
  **Age when started smoking**                                                                                                 
   Never smoker                                                149     1.00                253     1.00                228     1.00
   20+ years                                                   75      0.71 (0.53--0.94)   61      0.77 (0.57--1.04)   67      0.70 (0.52--0.93)
   17--19 years                                                61      0.70 (0.51--0.95)   13      0.36 (0.20--0.64)   38      0.58 (0.41--0.84)
  \<16 years                                                   72      0.63 (0.47--0.84)   14      0.58 (0.33--1.02)   52      0.73 (0.53--1.01)
                                                               Trend   0.001               Trend   \<0.001             Trend   0.006
  **Passive smoking in childhood**                             53      1.25 (0.70--2.24)   103     0.88 (0.60--1.32)           
  **Passive smoking at home/work**                             54      0.71 (0.40--1.23)   84      0.68 (0.43--1.08)           

Models adjusted for educational level and sex (where appropriated) and stratified by centre and age at recruitment.

Excluding Sweden (*N* = 53 291) and missing for 10 876 subjects who were excluded from this model.

###### 

Hazard ratios (HRs) and relative 95% confidence intervals (CIs) from Cox-regression models investigating smoking variables in relation to PD onset in each country separately and *p*-value for heterogeneity

                                                                 Italy               Spain               UK                  The Netherlands     Greece               Germany             Sweden              
  -------------------------------------------------------------- ------------------- ------------------- ------------------- ------------------- -------------------- ------------------- ------------------- ---------
  **PD/total**                                                   64/40 148           101/24 924          200/27 980          13/16 909           92/25 845            50/25 436           195/53 291          
  **Incidence rate per 10 000 person/years**                     1.32                3.08                5.47                0.73                3.70                 1.74                2.66                
                                                                                                                                                                                                              
                                                                 HR (95% CI)         HR (95% CI)         HR (95% CI)         HR (95% CI)         HR (95% CI)          HR (95% CI)         HR (95% CI)         p-value
                                                                                                                                                                                                              
  **Smoking status at recruitment**                                                                                                                                                                           
   Never smokers                                                 1.00                1.00                1.00                1.00                1.00                 1.00                1.00                0.099
   Former smokers                                                1.11 (0.61--2.02)   0.63 (0.33--1.22)   0.91 (0.66--1.23)   0.40 (0.11--1.48)   0.71 (0.378--1.32)   0.62 (0.34--1.16)   0.74 (0.54--1.03)   
   Current smokers                                               0.75 (0.38--1.48)   0.66 (0.36--1.21)   0.75 (0.46--1.21)   0.27 (0.03--2.17)   0.34 (0.14--0.84)    0.24 (0.07--0.81)   0.28 (0.17--0.48)   
  **Duration of smoking** [^a^](#tblfn16){ref-type="table-fn"}                                                                                                                                                
   Never                                                         1.00                1.00                1.00                1.00                1.00                 1.00                1.00                0.143
  \<20 years                                                     1.58 (0.81--3.11)   0.94 (0.43--2.07)   0.74 (0.46--1.20)   0.33 (0.04--2.62)   0.50 (0.15--1.67)    0.61 (0.28--1.30)   0.89 (0.60--1.31)   
   20--29 years                                                  0.78 (0.35--1.77)   0.67 (0.29--1.51)   0.96 (0.59--1.57)   0.38 (0.05--3.06)   0.79 (0.30--2.06)    0.76 (0.32--1.77)   0.59 (0.35--0.97)   
   30+ years                                                     0.73 (0.37--1.45)   0.56 (0.30--1.05)   0.77 (0.53--1.12)   0.38 (0.08--1.80)   0.54--0.28--1.02)    0.27 (0.09--0.78)   0.31 (0.19--0.50)   
  Trend                                                          0.276               0.060               0.229               0.158               0.070                0.015               P\<0.001            
  **Smoking intensity** [^b^](#tblfn17){ref-type="table-fn"}                                                                                                                                                  
   Never                                                         1.00                1.00                1.00                1.00                1.00                 1.00                --                  0.397
  \<12 cigarettes/day                                            1.08 (0.57--2.06)   0.97 (0.53--1.77)   0.91 (0.63--1.34)   0.40 (0.11--1.52)   0.60 (0.25--1.46)    0.37 (0.15--0.91)   --                  
   12+ cigarettes/day                                            0.62 (0.28--1.37)   0.39 (0.19--0.80)   0.68 (0.45--1.00)   --                  0.54 (0.29--1.01)    0.59 (0.28--1.25)   --                  
  Trend                                                          0.297               0.014               0.062               0.051               0.051                0.075               --                  

Calculated after excluding 4620 (of which 29 PD) missing values.

Calculated after excluding Sweden (*N* = 53 291) and 10 876 missing values (of which 55 PD cases).

Studied individually, all smoking variables were found to be inversely associated with the risk of PD with clear-cut dose--response relationships. For age when started and quit smoking, a monotonic trend across categories was not evident ([Table 2](#dyy230-T2){ref-type="table"}). The analysis of residuals of Schonefeld showed no evidence of non-proportionality over the follow-up period. The smoothed curves for former smokers ([Figure 2A](#dyy230-F2){ref-type="fig"}) and for current smokers ([Figure 2B](#dyy230-F2){ref-type="fig"}) were flat, showing that beta-coefficient (log hazard ratio) estimates did not vary during follow-up (time) ([Figure 2](#dyy230-F2){ref-type="fig"}). Smoking variables were associated with inverse risk of both mid-age and late-onset PD; however, all the estimates are stronger in the latter. All the risk estimates, conversely, remain highly consistent for the akinetic-rigid and tremor-dominant forms at onset ([Table 5](#dyy230-T5){ref-type="table"}). The Postural Instability/Gait Disturbance (PIGD) form could not be studied individually, as it included only 42 subjects.[@dyy230-B16]

![Analysis of the residuals of Schoenfeld residuals to assess the proportionality assumption comparing former smokers (**A**) and current smokers (**B**) with never smokers. Figures represent plots of beta-coefficient estimates (log hazard ratios) for former smokers (**A**) and current smokers (**B**) against follow-up (time) in years. The darker (blue) line represents a smoothed curve of scaled Shoenfeld residuals with 95% confidence intervals (darker (blue) dotted lines), whereas the lighter (red) line represents a beta-coefficient estimate from a Cox-regression model.](dyy230f2){#dyy230-F2}

###### 

Hazard ratios (HRs) and relative 95% confidence intervals (CIs) for Cox regressions analysing risk of PD at early and older age of onset and in tremor-dominant or akinetic-rigid forms

                                                               Mid-age PD onset   Late PD onset       Tremor-dominant PD[^a^](#tblfn18){ref-type="table-fn"}   Akinetic-rigid PD[^a^](#tblfn18){ref-type="table-fn"}                                   
  ------------------------------------------------------------ ------------------ ------------------- -------------------------------------------------------- ------------------------------------------------------- ----- ------------------- ----- -------------------
  **Smoking status at recruitment**                                                                                                                                                                                                                    
   Never smoker                                                215                1.00                187                                                      1.00                                                    140   1.00                102   1.00
   Former smoker                                               119                0.89 (0.70--1.14)   113                                                      0.69 (0.53--0.89)                                       66    0.84 (0.61--0.16)   38    0.66 (0.44--0.98)
   Current smoker                                              51                 0.51 (0.37--0.69)   30                                                       0.48 (0.32--0.72)                                       28    0.47 (0.31--0.73)   17    0.39 (0.23--0.67)
  **Duration of smoking**                                                                                                                                                                                                                              
   Never smokers                                               215                1.00                187                                                      1.00                                                    140   1.00                102   1.00
  \<20 years                                                   56                 0.90 (0.67--1.23)   36                                                       0.76 (0.53--1.11)                                       34    1.00 (0.67--1.49)   16    0.64 (0.37--1.10)
   20--29 years                                                37                 0.68 (0.47--0.97)   32                                                       0.81 (0.55--1.21)                                       25    0.82 (0.52--1.30)   11    0.49 (0.26--0.93)
   30+ years                                                   66                 0.60 (0.45--0.81)   57                                                       0.47 (0.34--0.64)                                       31    0.46 (0.30--0.69)   27    0.53 (0.34--0.84)
                                                                                  \<0.001                                                                      \<0.001                                                       \<0.001                   0.002
  **Smoking intensity** [^b^](#tblfn19){ref-type="table-fn"}                                                                                                                                                                                           
   Never smokers                                               154                1.00                130                                                      1.00                                                    91    1.00                62    1.00
  \<12 cigarettes/day                                          50                 0.84 (0.60--1.18)   41                                                       0.74 (0.51--1.08)                                       28    0.93 (0.58--1.47)   14    0.58 (0.31--1.07)
   12+ cigarettes/day                                          55                 0.62 (0.44--0.87)   35                                                       0.46 (0.31--0.69)                                       20    0.46 (0.27--0.78)   18    0.50 (0.27--0.91)
                                                                                  0.006                                                                        \<0.001                                                       0.007                     0.014

Information on subtype is not available for 324 PD cases.

Restricted to the whole cohort except Sweden.

The competing-risk analysis using mortality as a competing factor yielded much stronger point estimates but largely overlapping 95% confidence intervals (CIs) for all the active smoking variables: smoking for 30+ years or 12+ cigarettes/day is associated with a ∼55% reduced risk of PD compared with never smokers ([Table 2](#dyy230-T2){ref-type="table"}).

Hazard ratios (HRs) of smoking intensity and duration from Cox models stratified for smoking status at recruitment are shown in [Figure 3](#dyy230-F3){ref-type="fig"}. Point estimates in current smokers are consistently lower compared with those in former smokers, although the pattern of risk reduction is highly comparable across the two groups, all trends had *p* ≤ 0.001 and no interaction was detected between smoking duration and intensity and smoking status (*p*-value for interaction 0.823 and 0.537, respectively).

![HRs and relative 95% CIs for smoking duration (**A**) and intensity (**B**) among former (continuous line) and current (dashed line) smokers at recruitment in the EPIC study.](dyy230f3){#dyy230-F3}

Analysis of passive smoking, although hampered by limited power, showed no association between exposure to passive smoking in infancy and risk of PD. However, an inverse association was found between passive-smoking exposure at home or at work and risk of PD (HR 0.70, 95% CI 0.49--0.99), which was replicated among never smokers only (HR 0.71, 95% CI 0.46--1.10).

The sensitivity analysis including definite and very likely PD only yielded strikingly similar results ([Table 3](#dyy230-T3){ref-type="table"}). All associations were, if anything, strengthened despite the widening of CIs due to the smaller sample size. An inverse association between age when quitting smoking and risk of PD was also suggested by the sensitivity analysis.

Discussion
==========

This study provides unique data on the inverse association between cigarette smoking and risk of PD in a large, well-established cohort study, supporting previous findings,[@dyy230-B3]^,^[@dyy230-B4]^,^[@dyy230-B8] and allows testing of explanations other than a direct protective effect. Overall, data coming from the NeuroEPIC4PD study show a robust inverse association between smoking status at recruitment and PD risk, with a dose--response relationship between PD risk and smoking duration and intensity. Of particular interest is the replication of the main findings of the inverse relationship between smoking and PD among different subtypes of the disease. This is a novel finding, as, to our knowledge, clinical subtypes have not been investigated to date in such an epidemiological setting.

Delaying effect of smoking
--------------------------

The fact that proportional assumption hypothesis is verified demonstrates that the risk does not vary over the follow-up period, and this argues against a delaying effect of smoking on PD onset ([Figure 1B](#dyy230-F1){ref-type="fig"}). Moreover, at odds with some previous reports,[@dyy230-B3]^,^[@dyy230-B8] our findings of an inverse relationship between smoking variables and risk of PD are not weakened when the analysis is restricted to old-age onset PD (70+ years). Taken together, these results are not supportive of the hypothesis that smoking might delay, rather than prevent, PD onset, as previously suggested.[@dyy230-B3]^,^[@dyy230-B8] However, despite this piece of evidence being important and informative per se, the distinction between delaying and preventing any disease onset is somewhat artificial, as these mechanisms might coincide from both a clinical and a biological point of view.

Reverse causality
-----------------

If an inverse causal relationship---accounting for subjects with a preclinical dopaminergic change who therefore might find it easier to quit smoking---was responsible for the observed inverse association between smoking and PD, the dose--response relationship between smoking duration and intensity should not hold true among former smokers ([Figure 1C](#dyy230-F1){ref-type="fig"}). The fact that the risk of PD was reduced among current and former smokers argues against this possible explanation. Furthermore, the inverse association between time since cessation and PD reinforces the idea that reverse causality is not a likely explanation of the findings: having quit smoking 9--18 years before recruitment into the study (therefore up to 30 years before disease onset) still confers a reduced risk of PD compared with never smokers. This results are in line with previous observational studies that showed an inverse association between parental smoking and PD in the offspring;[@dyy230-B7] also, the use of parental smoking as an instrumental variable overcomes the potential for a reverse-causality effect.

Unmeasured confounding
----------------------

Whereas it was not possible to account for personality trait, its unmeasured confounding effect can be overcome by using exposure to passive smoking in relation to PD onset. Risk propensity is likely to influence one's attitude towards active smoking, whereas passive smoking is more likely to be related to these personal characteristics in a weaker way (e.g. smokers tend to have smoking partners). The inverse association between passive smoking and PD onset, whose point estimate has been replicated among never smokers only, argues against considering personality trait as a major confounder. These results are in line with previous reports showing how adjusting for sensation-seeking score only slightly attenuated the inverse association between smoking and PD suggesting an independent effect[@dyy230-B20] and with observations that personality traits such as neuroticism and introversion do not explain the inverse association between smoking and PD risk.[@dyy230-B21]

Biological plausibility
-----------------------

A number of substances present in tobacco have been proposed as potentially responsible for the inverse association between smoking and PD. One of these is 2,3,6-trimethyl-1,4-naphthoquinone (TMN), an inhibitor of monoamine oxidase (MAO) A and B activity.[@dyy230-B22] TMN partially protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurodegeneration in mice by reducing endogenous dopamine metabolism and consequently decreasing oxidative stress. Synthetic MAO B inhibitors are currently used in the treatment of PD, providing symptomatic relief, but they may also protect against nigrostriatal damage decreasing dopamine metabolism, as suggested by delayed need for antiparkinsonian drugs in a recent clinical trial.[@dyy230-B23] Another candidate is nicotine itself, given the close anatomical relationship between the nicotinic cholinergic and dopaminergic neurotransmitter systems in the striatum. Nicotine influences also the dopaminergic activity by acting at nicotinic receptors on dopaminergic terminals and modulating dopamine release.[@dyy230-B24]^,^[@dyy230-B25] The role of nicotine is being investigated in a randomized trial in patients with early PD, but a role of other tobacco components cannot be excluded.

Being exposed to passive smoke is associated with a reduced risk of 30% (HR 0.70, 95% CI 0.49--0.99) and being a light smoker with a 20% reduced risk (HR 0.80, 95% CI 0.62--1.02) ([Table 2](#dyy230-T2){ref-type="table"}). Although the difference could be due to limits in the design (data on passive smoking were available for a subset of the sample), it cannot be excluded that passive smoking has a stronger effect than one would expect from a pure equivalence of levels of exposure. Passive smoking has been demonstrated to be as mutagenic as active smoking,[@dyy230-B26] although earlier studies suggest that the overall chemical composition of passive smoking might not represent only the diluted composition of side-stream smoking, given the sorbing and desorbing properties of some volatile and semi-volatile organic compounds in passive smoking.[@dyy230-B27]

The main strengths of this study are the prospective design, the validated clinical outcome,[@dyy230-B28] the large sample and the detailed information on smoking patterns. This allowed a powered recall-bias-free analysis of smoking patterns in relation to PD onset. The main limitation of this study, however, is the lack of repeated smoking measurements over time, which might introduce some exposure misclassification, decreasing our ability to study smoking patterns in relation to PD onset. This is particularly true for outcomes ascertained many years after recruitment. However, the smoking pattern analyses repeated separately for PD cases ascertained within and after 8 years since recruitment yield highly consistent results (data not shown).

Conclusions
===========

In conclusion, the present findings are consistent with a protective effect of smoking on the risk of PD. Point estimates of smoking status are strong, with a strong exposure--response relationship of smoking intensity and duration. The consistency across different disease subtypes suggests that the putative protective effect might spread to the entire clinical spectrum of the disease. Finally, the inverse association found between passive smoking and PD is supported by a consistent finding among never smokers and points towards a true biological effect not mediated by personality type. Although smoking to prevent PD cannot be recommended given the multiple adverse effects of smoking, our results confirming an inverse association warrants further research on the mechanisms involved. In particular, the use of Mendelian randomization and biomarkers of long-term cigarette-smoke exposure should provide compelling final evidence on the inverse association between smoking and PD.
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